

## ESTIMATED ANNUALIZED BURDEN HOURS—Continued

Type of respondent	Number of respondents	Estimated number of responses per respondent	Average burden hours per response	Annual burden hours requested
Total .....	13,218	.....	.....	33,242

Dated: May 11, 2016.

**Lawrence A. Tabak,**

*Deputy Director, National Institutes of Health.*

[FR Doc. 2016-11618 Filed 5-16-16; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Government-Owned Inventions; Availability for Licensing

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** The invention listed below is owned by an agency of the U.S. Government and is available for licensing and/or co-development in the U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing and/or co-development.

**ADDRESSES:** Invention Development and Marketing Unit, Technology Transfer Center, National Cancer Institute, 9609 Medical Center Drive, Mail Stop 9702, Rockville, MD 20850-9702.

#### FOR FURTHER INFORMATION CONTACT:

Information on licensing and co-development research collaborations, and copies of the U.S. patent applications listed below may be obtained by contacting: Attn. Invention Development and Marketing Unit, Technology Transfer Center, National Cancer Institute, 9609 Medical Center Drive, Mail Stop 9702, Rockville, MD 20850-9702, Tel. 240-276-5515 or email [ncitechtransfer@mail.nih.gov](mailto:ncitechtransfer@mail.nih.gov). A signed Confidential Disclosure Agreement may be required to receive copies of the patent applications.

#### SUPPLEMENTARY INFORMATION:

Technology description follows.

*Title of invention:* Method for Purifying Antibodies.

*Description of Technology:* This technology is a method for purifying a biologic composition, comprising

diafiltering the biologic composition into a composition comprising phosphate buffered saline (PBS) to obtain a purified composition. The method is particularly useful for removing one or more impurities from the biologic composition, such as bis(2-hydroxyethyl)amino-tris(hydroxymethyl)methane (Bis-tris). The technology is directed to large scale manufacturing of Chimeric 14.18 (Ch14.18) monoclonal antibodies. Ch14.18 is an anti-GD2 monoclonal antibody and has been described in Gillies *et al.*, *Journal of Immunological Methods* 125:191-202 (1989).

#### *Potential Commercial Applications:*

- Large scale manufacturing of chimeric monoclonal antibodies
- *Value Proposition:*
- Cost effective means of removing impurities to produce GMP grade chimeric antibodies for regulatory approval.

*Development Stage:* Clinical Phase II, FDA/EMA approved Chemistry, Manufacturing and Controls (CMC) large scale manufacturing to produce GMP grade chimeric antibodies.

*Inventor(s):* David A. Meh (United Therapeutics Corporation), Timothy Atolagbe (United Therapeutics Corporation), G. Mark Farquharson (United Therapeutics Corporation), Samir Shaban (National Cancer Institute), Mary Koleck (National Cancer Institute), George Mitra (National Cancer Institute).

#### *Intellectual Property:*

HHS Ref. No. E-291-2014/0-US-01, corresponding to US Provisional Patent App. No. 62/028,994, filed July 25, 2014, entitled "Method for Purifying Antibodies using PBS"

HHS Ref. No. E-291-2014/0-US-02, corresponding to US Patent App. No. 14/809,211, filed July 25, 2015, entitled "Method for Purifying Antibodies using PBS"

HHS Ref. No. E-291-2014/0-PCT-03, corresponding to International Patent App. No. PCT/US2015/042241, filed July 27, 2015, entitled "Method for Purifying Antibodies"

#### *Publications:*

1. FDA published document: [http://www.accessdata.fda.gov/drugsatfda\\_docs/nda/2015/125516Orig1s000TOC.cfm](http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125516Orig1s000TOC.cfm)

2. US Food and Drug Administration. FDA approves first therapy for high-risk neuroblastoma. <http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm437460.htm>

3. WO2016015048 METHOD FOR PURIFYING ANTIBODIES <https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2016015048>

*Contact Information:* Requests for copies of the patent application or inquiries about licensing, research collaborations, and co-development opportunities should be sent to John D. Hewes, Ph.D., email: [john.hewes@nih.gov](mailto:john.hewes@nih.gov).

Dated: May 11, 2016.

**John D. Hewes,**

*Technology Transfer Specialist, Technology Transfer Center, National Cancer Institute.*

[FR Doc. 2016-11556 Filed 5-16-16; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Government-Owned Inventions; Availability for Licensing

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** The invention listed below is owned by an agency of the U.S. Government and is available for licensing and/or co-development in the U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing and/or co-development.

**ADDRESSES:** Invention Development and Marketing Unit, Technology Transfer Center, National Cancer Institute, 9609 Medical Center Drive, Mail Stop 9702, Rockville, MD 20850-9702.

#### FOR FURTHER INFORMATION CONTACT:

Information on licensing and co-development research collaborations, and copies of the U.S. patent applications listed below may be

obtained by contacting: Attn. Invention Development and Marketing Unit, Technology Transfer Center, National Cancer Institute, 9609 Medical Center Drive, Mail Stop 9702, Rockville, MD 20850-9702, Tel. 240-276-5515 or email [ncitechtransfer@mail.nih.gov](mailto:ncitechtransfer@mail.nih.gov). A signed Confidential Disclosure Agreement may be required to receive copies of the patent applications.

**SUPPLEMENTARY INFORMATION:**

Technology description follows.

*Title of invention:* Improved Pepper Spray for Repellency and Incapacitation.

*Description of Technology:* Non-lethal means of temporarily incapacitating a person are greatly needed for law enforcement and for personal protection. A common approach is to use pepper spray. Although current pepper sprays are effective, they cause pain for excessively long periods, and could be life threatening for people who suffer from asthma and have hypersensitive airways. This technology describes a composition for use in an aerosol or spray, that when administered, causes a painful stimulation and incapacitates a person for only a brief period. This technology may improve safety over currently available pepper sprays.

*Potential Commercial Applications:*

- Law enforcement (policing, riot control, crowd control)
- Incapacitating agent for use in hostage situations
- Personal self-defense

*Value Proposition:*

- Incapacitating pepper spray with reduced toxicity and enhanced safety.
- May reduce potential agency liability in case of an adverse response of an individual who was sprayed (due to reduced toxicity may not be as life threatening to those suffering from asthma or have hypersensitive airways as standard pepper sprays).

- Mixture can be incorporated into a spray, aerosol, or other dispersions.

*Development Stage:* Basic (Target ID).

*Inventor(s):* Peter M. Blumberg (NCI), Larry V. Pearce (NCI).

*Intellectual Property:*

HHS Reference No. E-048-2010/0. U.S. Provisional Application 61/340,063 (HHS Reference No. E-048-2010/0-US-01) filed March 12, 2010 entitled, "Improved Pepper Spray for Repellency and Incapacitation of People and Animals".

PCT Application PCT/US2011/028132 (HHS Reference No. E-048-2010/0-PCT-02) filed March 11, 2011 entitled, "Agonist/Antagonist Compositions and Methods of Use".

Canada: Application 2,792, 878 (HHS Reference No. E-048-2010/0-CA-03)

filed March 11, 2011 entitled, "Agonist/Antagonist Compositions and Methods of Use" (Pending).

U.S. Patent Application 13/634,447 (HHS Reference No. E-048-2010/0-US-04) filed September 12, 2012 entitled, "Agonist/Antagonist Compositions and Methods of Use".

U.S. Patent Application 15/010,830 (HHS Reference No. E-048-2010/0-US-05) filed January 29, 2016 entitled, "Agonist/Antagonist Compositions and Methods of Use" (Pending).

*Collaboration Opportunity:* Researchers at the NCI seek licensing for use as a non-lethal incapacitation agent.

*Contact Information:* Requests for copies of the patent application or inquiries about licensing, research collaborations, and co-development opportunities should be sent to John D. Hewes, Ph.D., email: [john.hewes@nih.gov](mailto:john.hewes@nih.gov).

Dated: May 11, 2016.

**John D. Hewes,**

*Technology Transfer Specialist, Technology Transfer Center, National Cancer Institute.*

[FR Doc. 2016-11555 Filed 5-16-16; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Allergy and Infectious Diseases; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Allergy and Infectious Diseases Special Emphasis Panel; Investigator Initiated Extended Clinical Trial (R01).

*Date:* June 6, 2016.

*Time:* 1:00 p.m. to 2:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health 3C100, 5601 Fishers Lane, Rockville, MD 20892 (Telephone Conference Call).

*Contact Person:* Yong Gao, Ph.D., Scientific Review Officer Scientific Review Program,

Division of Extramural Activities, Room #3G13B, National Institutes of Health/NIAID, 5601 Fishers Lane, MSC 9823, Rockville, MD 20892-7616, (240) 669-5048, [yong.gao@nih.gov](mailto:yong.gao@nih.gov).

*Name of Committee:* National Institute of Allergy and Infectious Diseases Special Emphasis Panel; Investigator Initiated Extended Clinical Trial (R01).

*Date:* June 6, 2016.

*Time:* 2:30 p.m. to 3:30 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 3C100, 5601 Fishers Lane, Rockville, MD 20892 (Telephone Conference Call).

*Contact Person:* Yong Gao, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, Room #3G13B, National Institutes of Health/NIAID, 5601 Fishers Lane, MSC 9823, Rockville, MD 20892-7616, (240) 669-5048, [gao@nih.gov](mailto:gao@nih.gov).

*Name of Committee:* Microbiology, Infectious Diseases and AIDS Initial Review Group; Microbiology and Infectious Diseases Research Committee.

*Date:* June 9-10, 2016.

*Time:* 12:00 p.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Room 3F100, 5601 Fishers Lane, Rockville, MD 20892 (Telephone Conference Call).

*Contact Person:* Frank S. De Silva, Ph.D., Scientific Review Officer Scientific Review Program, Division of Extramural Activities, Room #3E72A, National Institutes of Health/NIAID, 5601 Fishers Lane, MSC 9834, Bethesda, MD 20892934, (240) 669-5023, [fdesilva@niaid.nih.gov](mailto:fdesilva@niaid.nih.gov).

*Name of Committee:* National Institute of Allergy and Infectious Diseases Special Emphasis Panel; Rapid Assessment of Zika Virus (ZIKV) Complications (R21).

*Date:* June 13, 2016.

*Time:* 9:30 a.m. to 4:30 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Room 3C100, 5601 Fishers Lane, Rockville, MD 20892 (Telephone Conference Call).

*Contact Person:* Uday K. Shankar, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, Room #3G21B, National Institutes of Health, NIAID, 5601 Fishers Lane, MSC 9823, Bethesda, MD 20892-9823, (240) 669-5051, [uday.shankar@nih.gov](mailto:uday.shankar@nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: May 11, 2016.

**Natasha M. Copeland,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2016-11553 Filed 5-16-16; 8:45 am]

**BILLING CODE 4140-01-P**